Although numerous anecdotal reports of health benefits associated with consumption of Aquamin existed, no objective research was carried out until Marigot Ltd. undertook to understand exactly how Aquamin could impact human health. Over 15 years, Marigot Ltd. have accumulated a large and growing body of research evaluating Aquamin in work spanning in vitro assays, numerous animal models and human trials. This portfolio of research has been conducted independently, and largely at academic institutions across the world, by investigators that are renowned in their respective fields. All researchers are encouraged to publish their results on Aquamin in peer-reviewed scientific journals. As such, this research can be accessed by all and has withstood critique from peers in the relevant field(s).
Aquamin has been demonstrated to have superior bioavailability than other, commonly available calcium sources and has beneficial effects on bone, inflammation, specifically osteoarthritic conditions, digestive health and cardiovascular health.
The current research programme for Aquamin is focused on three key areas: the role of Aquamin in bone health (including oesteoarthritis and osteoporosis), cognition and immuno-modulation (including cardiovascular diseases, colorectal cancer and skin). These research themes are all relevant to further supporting the role of Aquamin in healthy ageing. The research projects are structured to provide further in vitro information on the potential modes of action of Aquamin through the application of advanced proteomics and metabolomics technologies and are supported by in vivo animal and human trials measuring real effects in an ageing population to provide validated support for healthy ageing when using Aquamin in the diet. Preliminary results are exciting and provide further validation of the benefits of including Aquamin in diet and nutritional programmes.